Results 81 to 90 of about 3,987 (159)

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. [PDF]

Nat Med
Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD, NATRON study group.   +22 more
europepmc   +1 more source

DOMINICA protocol: A study of benralizumab for severe eosinophilic asthma in children. [PDF]

Pediatr Allergy Immunol
Guilbert TW, Jison M, Sjö LB, Werkström V, Grindebacke H, Durżyński T, Lal A, Grigg J.   +7 more
europepmc   +1 more source

Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab. [PDF]

J Asthma Allergy
Pavlov N, Bridevaux PO, Jandus P, Charbonnier F, Schuoler C, Wörner PM, Leuppi JD, Rothe T, Stolz D.   +8 more
europepmc   +1 more source

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. [PDF]

Nat Med
Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD, NATRON study group.   +22 more
europepmc   +1 more source

Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. [PDF]

Cancer Med
Lyu W, Xu R, Chen L, Lei W, Chen C, Liao J, Lin X, Ma R, Wen W, Li H.   +9 more
europepmc   +1 more source

Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study. [PDF]

J Asthma Allergy
Adrish M, DeMartino JK, Carstens D, Jackson M, Schinkel J, Wilson K, Tkacz J.   +6 more
europepmc   +1 more source

Blood eosinophil count as a biomarker for therapy guidance in COPD and asthma exacerbations. [PDF]

Breathe (Sheff)
Godallage AN, Afrose D, Valizadeh M, Beech A, Jensen JS, Sivapalan P.   +5 more
europepmc   +1 more source

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. [PDF]

ERJ Open Res
Mukherjee M, Tan NS, Huang C, Kim B, Radford K, Ju X, Venegas Garrido C, Kjarsgaard M, Rodríguez-Suárez E, Wechsler ME, Walker B, Börjesson Sjö L, Necander S, Ashkar A, Weidner J, Sehmi R, McCrae C, Khalidi N, Nair P.   +18 more
europepmc   +1 more source

Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study. [PDF]

Biomedicines
Piazzetta GL, Di Agostino S, Lobello N, Aloisio A, Di Vito A, Bria J, Filardo A, Coscarella I, Preianò M, Pelaia C, Lombardo N, Chiarella E.   +11 more
europepmc   +1 more source

The Impact of BMI on the Effect of Biologic Agents for Severe Asthma. [PDF]

Pulm Ther
Papadopoulou S, Komiotis C, Drakopanagiotakis F, Loukides S, Steiropoulos P.   +4 more
europepmc   +1 more source